Source: International Congress 2016 – Prognostic variables in lung cancer I



Rating:

Share or cite this content

Citations should be made in the following way:
Kento Sato (Yamagata, Japan), Kento Sato, Yoko Shibata, Sumito Inoue, Akirai Igarash, Yoshikane Tokairin, Keiko Yamauchi, Tomomi Kimura, Takako Nemoto, Masamichi Sato, Hiroshi Nakano, Yuki Abe, Isao Kubota. Serum hepcidin and iron are associated with non-small cell lung cancer stage. Eur Respir J 2016; 48: Suppl. 60, 2860

Member's Comments

No comment yet.

Related content which might interest you: Serum level of GFBP-1 and IGFBP-6 in patients with non-small cell lung cancer (NSCLC) during chemotherapy Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009 Procalcitonin serum levels in patients with stage IV non-small cell lung cancer in first line of chemotherapy Source: International Congress 2016 – Clinical aspects of lung cancer Year: 2016 Breast metastasis in association with non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 538s Year: 2005 Serum level of IGF-I and IGF-II in patients with non-small cell lung cancer (NSCLC) during chemotherapy Source: Eur Respir J 2004; 24: Suppl. 48, 82s Year: 2004 Role of chemokines in resectable non-small cell lung cancer (NSCLC) Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019 Evaluate soluble PD-L1 in plasma in advanced stage non-small cell lung cancer patients Source: Virtual Congress 2020 – Biological mechanisms of lung cancer Year: 2020 Lung cancer Source: Respipedia Article Year: 2018 24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC) Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 Association between C-reactive protein and survival in non-small cell lung cancer Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017 Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 Changes in lymphocyte subgroups of non-small cell lung cancer patients during chemotherapy Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers Year: 2015 CHD4 is associated with poor prognosis of non-small cell lung cancer patients through promoting tumor cell proliferation Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Soluble non-invasive markers in non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 459s Year: 2005 Prognostic value study of lung cancer molecular markers and value of mitochondrial activity in resected non-small cell lung cancer Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Circulating free DNA, new dynamic marker in nonsmall cell lung cancer patients? Source: Eur Respir J 2015; 46: 1548-1550 Year: 2015 Advanced non-small cell lung cancer in elderly patients Source: Breathe 2012; 9: 26-34 Year: 2012 Radio(chemo)therapy in locally advanced nonsmall cell lung cancer Source: Eur Respir Rev 2015; 25: 65-70 Year: 2016 Plasma leptin levels in nonsmall cell lung carcinoma (NSCLC) patients at the time of the diagnosis Source: Eur Respir J 2001; 18: Suppl. 33, 65s Year: 2001 Staging of lung cancer Source: Eur Respir Mon; 2009: 44: 150–168 Year: 2009